Importantly, the first clinical cases of EGFRM+ NSCLC with concurrent gene-fusions responding to the combination of EGFR-TKI and a specific inhibitor of the fused oncoprotein (e.g., ALK-, BRAF- or RET-inhibitor) are being reported, indicating the possibility of overcoming this mechanism of TKI-resistance by combinatorial therapy [35,36,37]. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.